Clinical Nurse Specialist Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Marcia Younker

Clinical Nurse Specialist, Psychiatric/Mental Health Jackson, GA Clinical Nurse Specialist

NPI 1609183755 CMS profile 11051216

825 S Mulberry St, D, Jackson, GA 30233

Open in the dashboard

General payments

$4,942

265 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marcia Younker of Jackson, GA is reported in the CMS Open Payments database as having received $4,942 across 265 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Clinical Nurse Specialist, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $801 46
2024 General $949 51
2023 General $1,329 72
2022 General $1,300 63
2021 General $563 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marcia Younker
  • Clinical Nurse Specialist, Psychiatric/Mental Health median
  • Middle half of Clinical Nurse Specialist, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Marcia Younker were reported at $801. Among 300 Clinical Nurse Specialist, Psychiatric/Mental Health profiles paid that year, the median was $245 and the middle half received between $78 and $929.

Show as a table
Year Marcia Younker Clinical Nurse Specialist, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $563 $153 $44–$540 $132
2022 $1,300 $207 $60–$748 $149
2023 $1,329 $197 $55–$898 $160
2024 $949 $189 $49–$804 $164
2025 $801 $245 $78–$929 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $910 70 payments
  2. Corium, Inc. $790 37 payments
  3. Otsuka America Pharmaceutical, Inc. $383 14 payments
  4. Neos Therapeutics, LP $369 18 payments
  5. Alkermes, Inc. $278 14 payments
  6. ITI, Inc. $272 14 payments
  7. Teva Pharmaceuticals USA, Inc. $257 14 payments
  8. Supernus Pharmaceuticals, Inc. $197 11 payments
  9. Alfasigma USA, Inc. $193 10 payments
  10. Ironshore Pharmaceuticals Inc. $177 8 payments
  11. Other $1,115 55 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,870 263 payments
  2. Education $71 2 payments
Products named General payments · program years 2021–2025
  1. Azstarys $790 37 payments
  2. VRAYLAR $737 56 payments
  3. REXULTI $383 14 payments
  4. Adzenys XR-ODT $354 17 payments
  5. LYBALVI $278 14 payments
  6. ARISTADA Cns $256 13 payments
  7. ARISTADA Cns $256 13 payments
  8. CAPLYTA $254 13 payments
  9. ARISTADA Cns $198 10 payments
  10. ARISTADA Cns $198 10 payments
  11. Other $2,194 117 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

206

Median for Certified Clinical Nurse Specialist: 344

Drug cost

$19,831

Median for Certified Clinical Nurse Specialist: $20,739

Branded share of claims

49.5%

Median for Certified Clinical Nurse Specialist: 20.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 12 $16,497
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 41 $1,879
Bupropion Xl Bupropion Hcl Brand 36 $627
Mirtazapine Generic 16 $426
Sertraline Hcl Generic 14 $133
Buspirone Hcl Generic 16 $116
Clonazepam Generic 36 $88
Trazodone Hcl Generic 22 $59
Citalopram Hbr Citalopram Hydrobromide Brand 13 $7

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,644 Part D prescribers listed as Certified Clinical Nurse Specialist; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $153
$153 12 —
REXULTI
  • Lundbeck LLC $54
  • Otsuka America Pharmaceutical, Inc. $51
$105 — —
JORNAY PM
  • Ironshore Pharmaceuticals Inc. $91
$91 — —
Qelbree
  • Supernus Pharmaceuticals, Inc. $80
$80 — —
Adzenys XR-ODT
  • Neos Therapeutics, LP $73
$73 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

265 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Psychiatric/Mental Health in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record